BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wahlin S, Harper P, Sardh E, Andersson C, Andersson DE, Ericzon BG. Combined liver and kidney transplantation in acute intermittent porphyria. Transpl Int. 2010;23:e18-e21. [PMID: 20028496 DOI: 10.1111/j.1432-2277.2009.01035.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 4.1] [Reference Citation Analysis]
Number Citing Articles
1 Lissing M, Vassiliou D, Floderus Y, Harper P, Yan J, Hagström H, Sardh E, Wahlin S. Risk for incident comorbidities, nonhepatic cancer and mortality in acute hepatic porphyria: A matched cohort study in 1244 individuals. J Inherit Metab Dis 2022. [PMID: 36546345 DOI: 10.1002/jimd.12583] [Reference Citation Analysis]
2 Ramai D, Deliwala SS, Chandan S, Lester J, Singh J, Samanta J, di Nunzio S, Perversi F, Cappellini F, Shah A, Ghidini M, Sacco R, Facciorusso A, Giacomelli L. Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic Review. Cancers (Basel) 2022;14:2947. [PMID: 35740611 DOI: 10.3390/cancers14122947] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
3 Ventura P, Ricci A. Givosiran for the treatment of acute hepatic porphyria. Expert Review of Clinical Pharmacology. [DOI: 10.1080/17512433.2022.2075848] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
4 Sardh E, Harper P. RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria. J Intern Med. [DOI: 10.1111/joim.13443] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Sirch C, Khanna N, Frassetto L, Bianco F, Artero ML. Diagnosis of acute intermittent porphyria in a renal transplant patient: A case report. World J Transplant 2022; 12(1): 8-14 [DOI: 10.5500/wjt.v12.i1.8] [Reference Citation Analysis]
6 Ricci A, Guida CC, Manzini P, Cuoghi C, Ventura P. Kidney Involvement in Acute Hepatic Porphyrias: Pathophysiology and Diagnostic Implications. Diagnostics (Basel) 2021;11:2324. [PMID: 34943561 DOI: 10.3390/diagnostics11122324] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Alcázar López C, Rodríguez Laiz GP, Sánchez Martínez R, Pascual Bartolome S, Ramia JM. Liver transplantation for intermittent acute porphyria resistant to medical treatment. Cir Esp (Engl Ed) 2021;99:695-7. [PMID: 34674987 DOI: 10.1016/j.cireng.2021.09.002] [Reference Citation Analysis]
8 da Fonseca Neto OCL, Moutinho LER, Filgueira NA, Jucá NT, Rabêlo PJM, de Melo PSV, Amorim AG, Lacerda CM. Recurrence of mild neuropathic pain, following deceased donor liver transplantation, in patient with acute intermittent porphyria: Could timing explain it? A case report. Journal of Liver Transplantation 2021;4:100039. [DOI: 10.1016/j.liver.2021.100039] [Reference Citation Analysis]
9 Lissing M, Nowak G, Adam R, Karam V, Boyd A, Gouya L, Meersseman W, Melum E, Ołdakowska-Jedynak U, Reiter FP, Colmenero J, Sanchez R, Herden U, Langendonk J, Ventura P, Isoniemi H, Boillot O, Braun F, Perrodin S, Mowlem E, Wahlin S; European Liver and Intestine Transplant Association. Liver Transplantation for Acute Intermittent Porphyria. Liver Transpl 2021;27:491-501. [PMID: 33259654 DOI: 10.1002/lt.25959] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
10 Desnick RJ, Balwani M, Anderson KE. Heme Biosynthesis and the Porphyrias in Children. Liver Disease in Children 2021. [DOI: 10.1017/9781108918978.030] [Reference Citation Analysis]
11 Bustad HJ, Kallio JP, Vorland M, Fiorentino V, Sandberg S, Schmitt C, Aarsand AK, Martinez A. Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators. Int J Mol Sci 2021;22:E675. [PMID: 33445488 DOI: 10.3390/ijms22020675] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
12 Tortorelli S, White AL, Raymond K. Disorders of porphyrin metabolism. Biochemical and Molecular Basis of Pediatric Disease 2021. [DOI: 10.1016/b978-0-12-817962-8.00031-7] [Reference Citation Analysis]
13 de Sousa Arantes Ferreira G, Claudio de Oliveira L, Roberto de Sousa Ulisses L, Luis Conde Watanabe A, Medeiros IN, Souto Siqueira Cardoso H, Creão da Costa Alves I, Martins de Almeida T, Viana de Lima L, Fontoura RP, Resende Sousa E Silva E, de Araújo PL. Combined Liver and Kidney Transplant in Acute Intermittent Porphyria: A Case Report. Am J Case Rep 2020;21:e927832. [PMID: 33203827 DOI: 10.12659/AJCR.927832] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
14 Knotek M, Novak R, Jaklin-Kelez A, Mrzljak A. Combined liver-kidney transplantation for rare diseases. World J Hepatol 2020; 12(10): 722-737 [PMID: 33200012 DOI: 10.4254/wjh.v12.i10.722] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Alcázar López C, Rodríguez Laiz GP, Sánchez Martínez R, Pascual Bartolome S, Ramia JM. Liver transplantation for intermittent acute porphyria resistant to medical treatment. Cir Esp (Engl Ed) 2020:S0009-739X(20)30275-X. [PMID: 33019962 DOI: 10.1016/j.ciresp.2020.08.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Lazareth H, Talbi N, Kamar N, Levi C, Moulin B, Caillard S, Frimat L, Chemouny J, Chatelet V, Vachey C, Snanoudj R, Lefebvre T, Karras A, Gouya L, Schmitt C, Puy H, Pallet N. Kidney transplantation improves the clinical outcomes of Acute Intermittent Porphyria. Mol Genet Metab 2020;131:259-66. [PMID: 32893121 DOI: 10.1016/j.ymgme.2020.08.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
17 Bustad HJ, Toska K, Schmitt C, Vorland M, Skjærven L, Kallio JP, Simonin S, Letteron P, Underhaug J, Sandberg S, Martinez A. A Pharmacological Chaperone Therapy for Acute Intermittent Porphyria. Mol Ther 2020;28:677-89. [PMID: 31810863 DOI: 10.1016/j.ymthe.2019.11.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
18 Fontanellas A, Ávila MA, Anderson KE, Deybach JC. Current and innovative emerging therapies for porphyrias with hepatic involvement. J Hepatol 2019;71:422-33. [PMID: 31102718 DOI: 10.1016/j.jhep.2019.05.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
19 Martini PGV, Guey LT. A New Era for Rare Genetic Diseases: Messenger RNA Therapy. Hum Gene Ther 2019;30:1180-9. [PMID: 31179759 DOI: 10.1089/hum.2019.090] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
20 Berraondo P, Martini PGV, Avila MA, Fontanellas A. Messenger RNA therapy for rare genetic metabolic diseases. Gut 2019;68:1323-30. [PMID: 30796097 DOI: 10.1136/gutjnl-2019-318269] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 11.0] [Reference Citation Analysis]
21 Wang B, Rudnick S, Cengia B, Bonkovsky HL. Acute Hepatic Porphyrias: Review and Recent Progress. Hepatol Commun 2019;3:193-206. [PMID: 30766957 DOI: 10.1002/hep4.1297] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 12.0] [Reference Citation Analysis]
22 Alfano G, Ventura P, Fontana F, Marcacci M, Ligabue G, Scarlini S, Franceschini E, Codeluppi M, Guaraldi G, Mussini C, Cappelli G. Rhodococcus equi Pneumonia in Kidney Transplant Recipient Affected by Acute Intermittent Porphyria: A Case Report. Transplant Proc 2019;51:229-34. [PMID: 30661897 DOI: 10.1016/j.transproceed.2018.02.213] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
23 Schmitt C, Lenglet H, Yu A, Delaby C, Benecke A, Lefebvre T, Letteron P, Paradis V, Wahlin S, Sandberg S, Harper P, Sardh E, Sandvik AK, Hov JR, Aarsand AK, Chiche L, Bazille C, Scoazec JY, To-Figueras J, Carrascal M, Abian J, Mirmiran A, Karim Z, Deybach JC, Puy H, Peoc'h K, Manceau H, Gouya L. Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver. J Intern Med 2018;284:78-91. [PMID: 29498764 DOI: 10.1111/joim.12750] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 12.6] [Reference Citation Analysis]
24 Malinzak EB, Knudsen NW, Udani AD, Vikraman D, Sudan DL, Miller TE. Perioperative Challenges in Liver Transplantation for a Patient With Acute Intermittent Porphyria. J Cardiothorac Vasc Anesth 2018;32:2716-20. [PMID: 29306617 DOI: 10.1053/j.jvca.2017.11.045] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
25 Manceau H, Gouya L, Puy H. Acute hepatic and erythropoietic porphyrias: from ALA synthases 1 and 2 to new molecular bases and treatments. Curr Opin Hematol 2017;24:198-207. [PMID: 28118224 DOI: 10.1097/MOH.0000000000000330] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
26 Balwani M, Wang B, Anderson KE, Bloomer JR, Bissell DM, Bonkovsky HL, Phillips JD, Desnick RJ; Porphyrias Consortium of the Rare Diseases Clinical Research Network. Acute hepatic porphyrias: Recommendations for evaluation and long-term management. Hepatology 2017;66:1314-22. [PMID: 28605040 DOI: 10.1002/hep.29313] [Cited by in Crossref: 84] [Cited by in F6Publishing: 88] [Article Influence: 14.0] [Reference Citation Analysis]
27 Fontanellas A, Ávila MA, Berraondo P. Emerging therapies for acute intermittent porphyria. Expert Rev Mol Med 2016;18:e17. [PMID: 27804912 DOI: 10.1017/erm.2016.18] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
28 Ahmad SB, Miller M, Hanish S, Bartlett ST, Hutson W, Barth RN, LaMattina JC. Sequential kidney-liver transplantation from the same living donor for lecithin cholesterol acyl transferase deficiency. Clin Transplant. 2016;30:1370-1374. [PMID: 27490864 DOI: 10.1111/ctr.12826] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
29 Oishi K, Arnon R, Wasserstein MP, Diaz GA. Liver transplantation for pediatric inherited metabolic disorders: Considerations for indications, complications, and perioperative management. Pediatr Transplant 2016;20:756-69. [PMID: 27329540 DOI: 10.1111/petr.12741] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
30 Lourenço CM, Anderson KE. Disorders of Haem Biosynthesis. Inborn Metabolic Diseases 2016. [DOI: 10.1007/978-3-662-49771-5_36] [Reference Citation Analysis]
31 Besur S, Schmeltzer P, Bonkovsky HL. Acute Porphyrias. The Journal of Emergency Medicine 2015;49:305-12. [DOI: 10.1016/j.jemermed.2015.04.034] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 4.8] [Reference Citation Analysis]
32 Karim Z, Lyoumi S, Nicolas G, Deybach JC, Gouya L, Puy H. Porphyrias: A 2015 update. Clin Res Hepatol Gastroenterol 2015;39:412-25. [PMID: 26142871 DOI: 10.1016/j.clinre.2015.05.009] [Cited by in Crossref: 107] [Cited by in F6Publishing: 107] [Article Influence: 13.4] [Reference Citation Analysis]
33 Pischik E, Kauppinen R. An update of clinical management of acute intermittent porphyria. Appl Clin Genet. 2015;8:201-214. [PMID: 26366103 DOI: 10.2147/tacg.s48605] [Cited by in Crossref: 105] [Cited by in F6Publishing: 114] [Article Influence: 13.1] [Reference Citation Analysis]
34 Planté-bordeneuve V, Salhi H. Introduzione sugli aspetti genetici delle neuropatie. EMC - Neurologia 2015;15:1-11. [DOI: 10.1016/s1634-7072(15)72178-1] [Reference Citation Analysis]
35 Unzu C, Melero I, Hervás-stubbs S, Sampedro A, Mancheño U, Morales-kastresana A, Serrano-mendioroz I, de Salamanca RE, Benito A, Fontanellas A. Helper-dependent adenovirus achieve more efficient and persistent liver transgene expression in non-human primates under immunosuppression. Gene Ther 2015;22:856-65. [DOI: 10.1038/gt.2015.64] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
36 Yasuda M, Erwin AL, Liu LU, Balwani M, Chen B, Kadirvel S, Gan L, Fiel MI, Gordon RE, Yu C, Clavero S, Arvelakis A, Naik H, Martin LD, Phillips JD, Anderson KE, Sadagoparamanujam VM, Florman SS, Desnick RJ. Liver Transplantation for Acute Intermittent Porphyria: Biochemical and Pathologic Studies of the Explanted Liver. Mol Med 2015;21:487-95. [PMID: 26062020 DOI: 10.2119/molmed.2015.00099] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 4.9] [Reference Citation Analysis]
37 Serrano-Mendioroz I, Sampedro A, Mora MI, Mauleón I, Segura V, Enríquez de Salamanca R, Harper P, Sardh E, Corrales FJ, Fontanellas A. Vitamin D-binding protein as a biomarker of active disease in acute intermittent porphyria. J Proteomics 2015;127:377-85. [PMID: 25979770 DOI: 10.1016/j.jprot.2015.05.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
38 Bonkovsky HL, Maddukuri VC, Yazici C, Anderson KE, Bissell DM, Bloomer JR, Phillips JD, Naik H, Peter I, Baillargeon G, Bossi K, Gandolfo L, Light C, Bishop D, Desnick RJ. Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium. Am J Med 2014;127:1233-41. [PMID: 25016127 DOI: 10.1016/j.amjmed.2014.06.036] [Cited by in Crossref: 130] [Cited by in F6Publishing: 107] [Article Influence: 14.4] [Reference Citation Analysis]
39 Besur S, Hou W, Schmeltzer P, Bonkovsky HL. Clinically important features of porphyrin and heme metabolism and the porphyrias. Metabolites. 2014;4:977-1006. [PMID: 25372274 DOI: 10.3390/metabo4040977] [Cited by in Crossref: 69] [Cited by in F6Publishing: 75] [Article Influence: 7.7] [Reference Citation Analysis]
40 Singal AK, Parker C, Bowden C, Thapar M, Liu L, McGuire BM. Liver transplantation in the management of porphyria. Hepatology 2014;60:1082-9. [PMID: 24700519 DOI: 10.1002/hep.27086] [Cited by in Crossref: 83] [Cited by in F6Publishing: 85] [Article Influence: 9.2] [Reference Citation Analysis]
41 Yin Z, Wahlin S, Ellis ECS, Harper P, Ericzon B, Nowak G. Hepatocyte Transplantation Ameliorates the Metabolic Abnormality in a Mouse Model of Acute Intermittent Porphyria. Cell Transplant 2014;23:1153-62. [DOI: 10.3727/096368913x666980] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
42 Harper P, Sardh E. Management of acute intermittent porphyria. Expert Opinion on Orphan Drugs 2014;2:349-68. [DOI: 10.1517/21678707.2014.891456] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
43 Desnick RJ, Balwani M, Anderson KE. Heme biosynthesis and the porphyrias. Liver Disease in Children 2014. [DOI: 10.1017/cbo9781139012102.031] [Reference Citation Analysis]
44 Desnick R, Balwani M, Anderson KE. Inherited Porphyrias. Reference Module in Biomedical Sciences 2014. [DOI: 10.1016/b978-0-12-801238-3.05571-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
45 Larion S, Caballes FR, Hwang SI, Lee JG, Rossman WE, Parsons J, Steuerwald N, Li T, Maddukuri V, Groseclose G, Finkielstein CV, Bonkovsky HL. Circadian rhythms in acute intermittent porphyria--a pilot study. Eur J Clin Invest 2013;43:727-39. [PMID: 23650938 DOI: 10.1111/eci.12102] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
46 Bishop DF, Tchaikovskii V, Nazarenko I, Desnick RJ. Molecular expression and characterization of erythroid-specific 5-aminolevulinate synthase gain-of-function mutations causing X-linked protoporphyria. Mol Med 2013;19:18-25. [PMID: 23348515 DOI: 10.2119/molmed.2013.00003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
47 Sardh E, Wahlin S, Björnstedt M, Harper P, Andersson DEH. High risk of primary liver cancer in a cohort of 179 patients with Acute Hepatic Porphyria. J Inherit Metab Dis 2013;36:1063-71. [DOI: 10.1007/s10545-012-9576-9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 3.8] [Reference Citation Analysis]
48 Bonkovsky HL, Guo J, Hou W, Li T, Narang T, Thapar M. Porphyrin and Heme Metabolism and the Porphyrias. In: Terjung R, editor. Comprehensive Physiology. Wiley; 2011. pp. 365-401. [DOI: 10.1002/cphy.c120006] [Cited by in Crossref: 85] [Cited by in F6Publishing: 99] [Article Influence: 8.5] [Reference Citation Analysis]
49 Desnick R, Balwani M, Anderson KE. Inherited Porphyrias. Emery and Rimoin's Principles and Practice of Medical Genetics 2013. [DOI: 10.1016/b978-0-12-383834-6.00104-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
50 Balwani M, Desnick RJ. The porphyrias: advances in diagnosis and treatment. Hematology 2012;2012:19-27. [DOI: 10.1182/asheducation.v2012.1.19.3795678] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
51 Jorns C, Ellis EC, Nowak G, Fischler B, Nemeth A, Strom SC, Ericzon BG. Hepatocyte transplantation for inherited metabolic diseases of the liver. J Intern Med. 2012;272:201-223. [PMID: 22789058 DOI: 10.1111/j.1365-2796.2012.02574.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 95] [Article Influence: 8.2] [Reference Citation Analysis]
52 Stewart MF. Review of hepatocellular cancer, hypertension and renal impairment as late complications of acute porphyria and recommendations for patient follow-up. J Clin Pathol. 2012;65:976-980. [PMID: 22851509 DOI: 10.1136/jclinpath-2012-200791] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 4.0] [Reference Citation Analysis]
53 Balwani M, Desnick RJ. The porphyrias: advances in diagnosis and treatment. Blood 2012;120:4496-504. [PMID: 22791288 DOI: 10.1182/blood-2012-05-423186] [Cited by in Crossref: 153] [Cited by in F6Publishing: 158] [Article Influence: 13.9] [Reference Citation Analysis]
54 Beliaev AM, Foliaki A, Ha L, Boswell DR. Acute non-specific abdominal pain with port-wine urine. ANZ J Surg 2012;82:478-9. [PMID: 22672404 DOI: 10.1111/j.1445-2197.2012.06089.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
55 Frei P, Minder EI, Corti N, Muellhaupt B, Geier A, Adams H, Dutertre JP, Rudiger A, Dutkowski P, Maggiorini M, Ganter CC. Liver Transplantation because of Acute Liver Failure due to Heme Arginate Overdose in a Patient with Acute Intermittent Porphyria. Case Rep Gastroenterol 2012;6:190-6. [PMID: 22649331 DOI: 10.1159/000338354] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
56 Unzu C, Sampedro A, Sardh E, Mauleón I, Enríquez de Salamanca R, Prieto J, Salido E, Harper P, Fontanellas A. Renal failure affects the enzymatic activities of the three first steps in hepatic heme biosynthesis in the acute intermittent porphyria mouse. PLoS One 2012;7:e32978. [PMID: 22412963 DOI: 10.1371/journal.pone.0032978] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
57 Dowman JK, Gunson BK, Mirza DF, Bramhall SR, Badminton MN, Newsome PN; UK Liver Selection and Allocation Working Party. Liver transplantation for acute intermittent porphyria is complicated by a high rate of hepatic artery thrombosis. Liver Transpl 2012;18:195-200. [PMID: 21618697 DOI: 10.1002/lt.22345] [Cited by in Crossref: 82] [Cited by in F6Publishing: 83] [Article Influence: 7.5] [Reference Citation Analysis]
58 Lourenço CM, Lee C, Anderson KE. Disorders of Haem Biosynthesis. In: Saudubray J, van den Berghe G, Walter JH, editors. Inborn Metabolic Diseases. Berlin: Springer Berlin Heidelberg; 2012. pp. 519-32. [DOI: 10.1007/978-3-642-15720-2_37] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
59 Hift RJ, Thunell S, Brun A. Drugs in porphyria: From observation to a modern algorithm-based system for the prediction of porphyrogenicity. Pharmacology & Therapeutics 2011;132:158-69. [DOI: 10.1016/j.pharmthera.2011.06.001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
60 Innala E, Andersson C. Screening for hepatocellular carcinoma in acute intermittent porphyria: a 15-year follow-up in northern Sweden. J Intern Med 2011;269:538-45. [PMID: 21198994 DOI: 10.1111/j.1365-2796.2010.02335.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 3.8] [Reference Citation Analysis]
61 Siegesmund M, van Tuyll van Serooskerken AM, Poblete-Gutiérrez P, Frank J. The acute hepatic porphyrias: current status and future challenges. Best Pract Res Clin Gastroenterol 2010;24:593-605. [PMID: 20955962 DOI: 10.1016/j.bpg.2010.08.010] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 3.5] [Reference Citation Analysis]